In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information to uncover distinctive, disease-related patterns. He speaks to our approach of using biomarkers to identify and stratify Alzheimer’s disease patient subgroups to find those patients that may respond to a specific therapy, aid in the identification of new therapeutic targets, and help develop future small molecule drugs.
